Funded by $34.6 million from the Department of Defense, the testing will focus on whether the drug can be used to prevent COVID-19 infections in physicians, nurses and military personnel.
Under the agreement, ImmunoTek Bio Centers will provide Mount Sinai with collection machines to gather plasma from recovered COVID-19 survivors. Mount Sinai will then ship the plasma to Emergent, which will use it to manufacture COVID-HIG.
“There is emerging evidence that convalescent plasma is an effective treatment for COVID-19 patients,” David Reich, MD, Mount Sinai Hospital’s president and COO, said in a July 8 news release. “Therefore, hyperimmune globulin may become an effective option in the prevention and treatment of COVID-19 currently, in the absence of a vaccine, as well as in the future, particularly for patients who do not develop immunity from a vaccine.”
More articles on pharmacy:
Walmart partners with PBM startup to increase prescription drug cost savings
Novavax gets $1.6B from Operation Warp Speed to expedite COVID-19 vaccine development
Early use of hydroxychloroquine reduced COVID-19 deaths, study says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
